OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
September 29, 2021
CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.
September 02, 2021
Intelligent analytical tools detect impurities to help ensure the quality of small-molecule drug ingredients.
May 02, 2021
Mass spectrometry and automation are growing in importance for protein characterization, but further improvements are still needed.
March 03, 2021
The need for real-time monitoring and control has spurred the development of new analytical tools.
February 02, 2021
Common approaches to analyze elemental impurities for compliance with regulatory requirements are robust but still have some limitations.
February 01, 2021
The £500,000 (US$686,294)-investment in mass spectrometry support will accelerate biologics development and approval.
June 29, 2020
Enhanced sensitivity and ultra-high detection speed provide improved robustness and operability.
February 02, 2020
Complex protein structures pose analytical challenges that can be addressed by advanced mass spectrometry technologies and workflows, which can be used to comprehensively characterize them.
October 31, 2019
The company is expanding its bioanalytical capacity and capabilities to support biologic drug development, cell and gene therapy development, and biomarker analysis.
September 16, 2019
EMA plans to issue new guidance, as US and European regulators respond to reports of nitrosamine contamination in H2 blockers, including Zantac, that contain rantidine.